BML-282

BML-282, a potent and selective inhibitor of the Krüppel-like factor 4 (KLF4) transcription factor, has garnered significant attention in scientific research due to its pivotal role in various cellular processes and disease pathogenesis. KLF4, a member of the Krüppel-like family of zinc finger transcription factors, regulates gene expression involved in cell differentiation, proliferation, and survival. BML-282 exerts its action by binding specifically to the zinc finger domain of KLF4, thereby disrupting its DNA-binding ability and transcriptional activity. This inhibition of KLF4 function has been investigated in diverse research areas, including cancer biology, stem cell research, and tissue engineering. In cancer studies, BML-282 has been utilized to explain the oncogenic functions of KLF4 and its contribution to tumor initiation, progression, and metastasis. Moreover, research has explored the potential of BML-282 in targeting KLF4-driven oncogenic pathways for the development of novel anti-cancer strategies. Furthermore, in stem cell research, BML-282 has been employed to modulate KLF4-mediated cellular reprogramming and differentiation processes, offering insights into the mechanisms underlying cell fate determination and pluripotency maintenance. Additionally, in tissue engineering applications, BML-282 has been investigated for its ability to regulate KLF4-mediated tissue regeneration and repair mechanisms, suggesting its potential utility in regenerative medicine approaches.